IN2014CN04251A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04251A
IN2014CN04251A IN4251CHN2014A IN2014CN04251A IN 2014CN04251 A IN2014CN04251 A IN 2014CN04251A IN 4251CHN2014 A IN4251CHN2014 A IN 4251CHN2014A IN 2014CN04251 A IN2014CN04251 A IN 2014CN04251A
Authority
IN
India
Prior art keywords
provides
present
compound
carbohydrate polymer
immunomodulatory
Prior art date
Application number
Other languages
English (en)
Inventor
Geoffrey Alan Pietersz
Clement Leong
Original Assignee
Ascend Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904656A external-priority patent/AU2011904656A0/en
Application filed by Ascend Biopharmaceuticals Ltd filed Critical Ascend Biopharmaceuticals Ltd
Publication of IN2014CN04251A publication Critical patent/IN2014CN04251A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN4251CHN2014 2011-11-09 2012-11-09 IN2014CN04251A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011904656A AU2011904656A0 (en) 2011-11-09 Immunomodulatory conjugates
PCT/AU2012/001387 WO2013067597A1 (fr) 2011-11-09 2012-11-09 Conjugués immunomodulateurs

Publications (1)

Publication Number Publication Date
IN2014CN04251A true IN2014CN04251A (fr) 2015-07-17

Family

ID=48288385

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4251CHN2014 IN2014CN04251A (fr) 2011-11-09 2012-11-09

Country Status (7)

Country Link
US (1) US10344261B2 (fr)
EP (1) EP2776070A4 (fr)
JP (1) JP2014532799A (fr)
CN (1) CN104661683A (fr)
AU (1) AU2012334825B2 (fr)
IN (1) IN2014CN04251A (fr)
WO (1) WO2013067597A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428561B2 (en) 2008-03-28 2016-08-30 The Regents Of The University Of California Polypeptide-polymer conjugates and methods of use thereof
AU2015205756A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating EGFR expressing tumors
AR100137A1 (es) 2014-04-22 2016-09-14 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina
US10278984B2 (en) 2014-05-02 2019-05-07 Nitor Therapeutics Guanosine as an immune potentiator mediated through toll receptors
EP4001311A1 (fr) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Combinaisons anti-pd-l1 pour le traitement des tumeurs
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN107249570B (zh) * 2014-11-21 2022-08-09 丹麦技术大学 用于局部药物释放的凝胶制剂
RS58356B1 (sr) 2015-03-06 2019-03-29 Hoffmann La Roche Jedinjenja benzazepin dikarboksamida
CN104804985B (zh) * 2015-05-27 2016-09-07 青岛橡胶谷知识产权有限公司 过盛气体收集装置
CN108472310B (zh) 2015-12-09 2021-08-03 加利福尼亚大学董事会 治疗眼部疾病或病症的缀合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
EP3464274B1 (fr) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Composés de benzazépine dicarboxamide à fonction amide secondaire
WO2017202704A1 (fr) 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Composés de benzazépine dicarboxamide à fonction amide tertiaire
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
JP6957629B2 (ja) 2016-10-11 2021-11-02 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． 非線状自壊性リンカーおよびそのコンジュゲート
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AU2017419352B2 (en) 2017-06-23 2024-05-30 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US20200140556A1 (en) * 2017-06-28 2020-05-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy
CN108129337B (zh) * 2018-01-09 2020-10-16 苏州亚科科技股份有限公司 一种三羟烷基氨基甲烷的制备方法
EA202092723A1 (ru) * 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
CR20200649A (es) 2018-05-25 2021-05-11 Primmune Therapeutics Inc Agosnistas de tlr7
WO2020056192A1 (fr) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Conjugués d'anticorps d'agonistes de récepteurs de type toll
WO2020190762A1 (fr) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Agonistes de tlr supportés par des macromolécules
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
BR112022010165A2 (pt) 2019-11-26 2022-08-09 Primmune Therapeutics Inc Agonistas de tlr7
AU2020446002A1 (en) 2020-04-29 2022-12-22 Shanghai Ringene Biopharma Co., Ltd. Benzothiazolyl biaryl compound, and preparation method and use
EP4153590A1 (fr) * 2020-05-21 2023-03-29 Ohio State Innovation Foundation Dérivés lipidiques fonctionnels et leurs utilisations
WO2023229891A1 (fr) * 2022-05-25 2023-11-30 Ayuvis Research, Inc. Nouvelles petites molécules immunomodulatrices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DK1027063T3 (da) * 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannosereceptorbærende cellelinje og antigensammensætning
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
AU2001263653B2 (en) 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
WO2005047507A1 (fr) 2003-11-12 2005-05-26 The Austin Research Institute Conjugue adn-excipient
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1988896A4 (fr) 2006-02-22 2011-07-27 3M Innovative Properties Co Conjugués du modificateur de réponse immune
WO2007149802A2 (fr) 2006-06-19 2007-12-27 3M Innovative Properties Company Formulation destinée à l'administration de modificateurs de réponse immune
EP2046812A4 (fr) 2006-07-25 2010-04-14 4G Vaccines Pty Ltd Vaccin contre le cancer comprenant un peptide dérivé d'épitopes de lymphocytes t de la mucine 1 (muc1)
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
RU2578420C2 (ru) * 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции

Also Published As

Publication number Publication date
EP2776070A4 (fr) 2016-02-10
AU2012334825A1 (en) 2014-06-19
EP2776070A1 (fr) 2014-09-17
US20150030626A1 (en) 2015-01-29
CN104661683A (zh) 2015-05-27
US10344261B2 (en) 2019-07-09
AU2012334825B2 (en) 2017-08-24
JP2014532799A (ja) 2014-12-08
WO2013067597A1 (fr) 2013-05-16

Similar Documents

Publication Publication Date Title
IN2014CN04251A (fr)
MX2015003416A (es) Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
EP2563366A4 (fr) Utilisations de conjugués phospholipidiques d'agonistes synthétiques de tlr7
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
AU2012335543A8 (en) HER3 antibodies and uses thereof
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX344972B (es) Oligonucleotidos inmunoestimulantes.
GB2518813A (en) OMV vaccine against Burkholderia infections
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PL2707010T3 (pl) Szczepy bakteryjne należące do rodzaju bifidobacterium do zastosowania w leczeniu hipercholesterolemii
MX364220B (es) Metodos de tratamientos de fibrosis.
PH12015500590B1 (en) Apixaban liquid formulations
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
EP3049536A4 (fr) Procédés et compositions concernant une thérapie anticancéreuse au moyen d'agents endommageant l'adn
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX2019004364A (es) Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
NZ628433A (en) Chitosan-derived compositions
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
EP2809775A4 (fr) Vaccin anti-cancer présentant un antigène de feuillet pluripotent
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
IN2014DN08407A (fr)
IN2014DN08093A (fr)
ZA201308256B (en) Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures